Dr. Henry Ji
Director, President and CEO
Henry Ji, Ph.D. co-founded and has served as a director of Sorrento Therapeutics, Inc. since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji has more than 18 years of biotechnology and biopharmaceutical experience.
Dr. Ji’s extensive knowledge of the industry in which we operate, as well as his unique role in our day-to-day operations as our Chief Executive Officer and President, allows him to bring to our board of directors a broad understanding of the operational and strategic issues we face. Dr. Ji also served as Sorrento’s Secretary from September 2009 to June 2011, Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999.
Dr. Ji is the holder of several issued and pending patents in the life science field and is the sole inventor of Sorrento Inc.’s intellectual property covering the G-MAB® library technology. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.
Senior Vice President, Chief Business Officer
Mr. Singh , joined Sorrento in January 2014 from Synta Pharmaceuticals, where he most recently served as SVP and Chief Business Officer.
Mr. Singh joined Synta in December 2010 from Spectrum Pharmaceuticals, where he served as Chief Operating Officer. At Spectrum, he led the commercial and business development teams responsible for the successful re-launch of Zevalin® and completed major partnerships for Zevalin (Cell Therapeutics) and Belinostat (TopoTarget). Prior to joining Spectrum, Mr. Singh was VP and Chief Commercial Officer at Novacea where he was responsible for securing major partnerships for the company’s lead compound, Asentar. Prior to Novacea, Mr. Singh led the launch of the proprietary division of American Pharmaceutical Partners-Abraxis Oncology and provided leadership in all aspects of commercial, and strategic development of the company’s flagship product, Abraxane®. Prior to Abraxis, Mr. Singh held multiple leadership positions in the oncology franchise at Hoffman-La Roche, where he led the launches of several oncology and supportive care products including Xeloda® and Kytril®. Mr. Singh holds an M.B.A. from the Stern School of Business at New York University and a B.A. from the University of North Carolina at Chapel Hill.
Dr. Vuong Trieu
Director and Chief Scientific Officer
Vuong Trieu, Ph.D., has been involved in drug discovery and development for over 20 years, including his contributions as co-inventor of Abraxane®.
Dr. Trieu has broad drug discovery and development experience having directly supported seven drug candidates from preclinical to clinical to commercialization, as well as broad regulatory experience across various territories: US, EMEA, KIKO, and others. Previously, Dr. Trieu was the Chief Executive Officer at IgDraSol. Before that, he was the Sr. Director of Pharmacology/Biology at Abraxis Bioscience/Celgene and led the drug discovery and preclinical development as well as pharmacokinetic and biomarker programs supporting Abraxis pipeline and its commercial product Abraxane®. There, Dr. Trieu led the preclinical, clinical and PK/biomarker development of Abraxane®, and was the co-inventor of the intellectual property covering Abraxane®. Previously, Dr. Trieu held positions at Genetic Therapy/Sandoz (leading the adenoviral gene therapy program against atherosclerosis), Applied Molecular Evolution (AME)/Eli Lilly (leading the expression, purification, and preclinical testing of mAb therapeutics) and Parker Hughes Center (Director of Cardiovascular Biology program that evaluated a series of small molecules and biologics against preclinical models of atherosclerosis, dyslipidemia, stroke, ALS, and restenosis).
Dr. Trieu has 34 peer-reviewed scientific articles and 30 patents and patent applications, and is also an active member of various professional societies including Endocrine Society, ASCO, and AACR. Dr. Trieu completed postdoctoral training at University of Chicago’s pediatric transplantation unit and Oklahoma Medical Research Foundation lipoprotein department. Dr. Trieu obtained his doctorate in Microbiology/Molecular Biology from the University of Oklahoma in 1989.
Chief Commercial Officer
George Uy has been responsible for the planning and launch of several successful drugs over the past 30 years.
Prior to joining Sorrento, Mr. Uy was Chief Commercial Officer at IgDraSol. He was also the Vice President of Commercial Operations at Spectrum Pharmaceuticals, where he helped transition Spectrum from development to commercialization, built the commercial organization and launched two successful oncology drugs. In 2003, Mr. Uy was hired as one of the first employees at Abraxis Bioscience to launch the breast cancer drug Abraxane® (nab-paclitaxel), which achieved sales exceeding $100 million in its first year. Mr. Uy started his career with F. Hoffmann-La Roche as a pharmaceutical sales representative, and later assumed senior executive positions responsible for the successful launch of several pharmaceutical products. Mr. Uy later relocated to F. Hoffmann-La Roche in Basel, Switzerland as International Product Manager for Roferon-A®. Mr. Uy established the commercial operations for Roche Shanghai, where he grew China sales significantly and launched several products. He later relocated to the U.S. and was responsible for launching Xeloda® (capecitabine), an oral chemotherapy drug for breast and colorectal cancer.
Mr. Uy received his B.A. in Medical Technology from the Cebu Institute of Medicine.
Richard G. Vincent
Executive Vice President and CFO
Richard G. Vincent has served as our Chief Financial Officer since February 2010. Mr. Vincent brings over 20 years of experience serving as Chief Financial Officer for privately-held and publicly-traded companies in the pharmaceutical and biopharmaceutical industries as well as serving in the public accounting industry for over nine years.
He combines general business expertise and capital-raising experience, with a deep knowledge of financial matters and financial reporting obligations of a public company. In addition, Mr. Vincent has extensive corporate governance and operational management experience, giving him a deep understanding of the challenges faced by public companies and allowing him to bring a variety of viewpoints and perspectives to our board of directors.
Since April 2008, Mr. Vincent has also served as a contract Chief Financial Officer for various other companies, including Elevation Pharmaceuticals, Inc., Meritage Pharma, Inc., Genoa Pharmaceuticals, Inc., Verus Pharmaceuticals, Inc., Chumby Industries, Inc. and Suneva Medical, Inc. From October 2004 to March 2009, Mr. Vincent served as Chief Financial Officer of Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing pediatric drug/device combination products for the treatment of asthma, allergies, and related diseases and conditions.
From October 2003 to October 2004, Mr. Vincent served as Chief Financial Officer of Women First HealthCare, Inc., a public specialty pharmaceutical company focused on women’s healthcare and dermatology. Mr. Vincent also served as Senior Director of Finance for Elan Pharmaceuticals, Inc., a public biopharmaceutical company engaged in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain, from October 2001 to October 2003. From November 1995 to October 2001, Mr. Vincent served in various senior management capacities for several wireless and technology companies. From 1987 to 1995, Mr. Vincent held a number of positions with Deloitte & Touche LLP, the last of which was senior manager, where he specialized in emerging growth and publicly-reporting companies.
Mr. Vincent became a Certified Public Accountant in California in 1989 and holds a B.S. degree in business with an emphasis in accounting from San Diego State University.
Zhenwei (David) Miao, Ph.D.
Chief Technical Officer
David Miao joined Sorrento in December 2013, bringing his experience in both small molecule and antibody drug discovery. As Chief Technical Officer, he heads the Company’s efforts for discovery and progression of novel ADCs towards IND candidates while also and advancing Sorrento’s ADC technology platform.
Prior to joining Sorrento, he was co-founder, President and Chief Scientific Officer of Concortis Biosystems, an ADC specialty company focused on creating next generation antibody therapeutics using proprietary conjugation technologies. Previously, he was the Director / Head of Chemistry and a member of the Senior R&D Team at Ambrx, where he led their chemistry research effort. Prior to that, Dr. Miao was a Principal Scientist at Enanta, where he was involved in several drug discovery programs, including discovery of an HCV drug candidate that is now in advanced clinical trials. Dr. Miao holds a B.S. in chemistry from Nankai University and a Ph.D. in chemistry from Peking University. He received his post doctorate training at Vanderbilt University Medical Center from 1997-2000.
Dr. Miao is co-author of more than 30 peer-reviewed papers and co-inventor of more than 50 patents.